Molekulyarno-geneticheskie osobennosti, kharakter metabolizma glyukozy i funktsiya endoteliya u bol'nykh metabolicheskim sindromom russkoy populyatsii
https://doi.org/10.14341/2072-0351-5585
Abstract
About the Authors
Ashot Musaelovich MkrtumyanElena Valer'evna Biryukova
N V Markina
References
1. Карпов Р. С. Современные проблемы атеросклероза: взгляд клинициста // Бюллетень сибирской медицины 2003; 3: 13-29.
2. Шахнович Р. М., Басинкевич А. Б. Маркеры воспаления и ОКС // Кардиология СНГ 2005; 3: 58-65.
3. Шестакова М. В., Бутрова С. А., Сухарева О. Ю. Метаболический синдром как предвестник развития сахарного диабета 2-го типа и сердечно-сосудистых заболеваний // Тер. архив 2007; 10: 5-8
4. Aguilar-Bryan L., Clement IV J. P., Gonzales Z. Molecular biology of adenosine triphospatesensitive potassium channels // Endocr Rew 1999; 78(1): 227-45.
5. Bagry H. S., Raghavendram S., Carli F. Metabolic syndrome and insulin resistance // An-esthesiology 2008; 108(3): 506-23.
6. Bao W., Srinivasan S. R., Berenson G. S. Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults: The Bogalusa Heart Study // Circulation 1996; 93(1): 54-9.
7. Beckman J. S., Koppenol W. H. Nitric oxide, superoxide, peroxynitrite: the good, the bad, and ugly // Am J Physiol 1996; 271: C1424-37.
8. Bennett C. N., Ross S. E., Longo K. A. et al. Regulation of Wnt signaling during adipo-genesis. // J Biol Chem 2002; 277: 30998-1004
9. Brian T. N., Jian-Mei L., Stephen B. et al. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity // Diabetes 2005; 54: 1082-9.
10. Cersosimo E., DeFronzo R. A. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases // Diabetes Metab Res Rev 2006; 22(6): 423-36.
11. Chan J. C. N., Cheung J. C. K., Stehouwer C. D. A. et al. The central roles of obesity-associated dyslipidemia, endothelial activation and cytokines in the metabolic syndrome an analysis by structural equation modeling // Int J Obes Relat Metab Disord 2002; 26: 994-1008.
12. Choi J. W., Pai S. H., Kim S. K. et al. Increase in nitric oxide concentration correlate strongly with body fat in obese humans // Clin Chemistry 2001; 47(6): 1106-9.
13. Cole S. A., Mitchell B. D., Hsueh W.-C. et al. The Pro12Ala variant of peroxisome proliferator-activated receptor-G2 (PPARG2) is associated with measures of obesity in Mexican Americans // Int J Obes 2000; 24: 522-4.
14. Dallaire P., Marette A. Obesity-linked insulin resistance: is the nitric oxide the missing link? // Canad J Diabetes 2004; 28(1): 59-66.
15. Florez J. C., Jablonski K. A., Bayley N. TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program // N Engl J Med 2006; 355(3): 241-50.
16. Grant S. F., Thorleifsson G., Reynisdottir I. et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes // Nat Genet 2006; 38: 320-3.
17. Hacket D., Davies G., Maseri A. Pre-existing coronary stenosis in patients with first myocardial infarction are not necessary severe // Europ. Heart J 1988; 9: 1317-23.
18. Irving R. J., Noon J. P., Watt G. C. M. et al. Activation of the endothelin system in in-sulin resistance // Q J Med 2001; 94: 312-26.
19. Lteif A., Vaishnava P., Baron A.D. Endothelin limits insulin action in obese/insulin-resistant humans // Diabetes 2007; 56: 728-34.
20. Lyssenko V., Lupi R., Piero Marchetti P. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. // J Clin Invest 2007; 117(8): 2155 63.
21. McCarthy J. J., Meyer J., Moliterno D. J. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients // Hum Genet 2003; 114: 87-98.
22. Nelson T. L., Fingerlin T. E., Moss L. et al. The PPARgamma Pro12Ala polymor-phism is not associated with body mass index or waist circumference among Hispanics from Colorado // Ann Nutr Metab 2007; 51(3): 252-7.
23. Nicklas B. J., van Rossum E. F. C., Berman D. M. Genetic variation in the peroxisome proliferator-activated receptor- 2 gene (Pro12Ala) affects etabolic responses to weight loss and subsequent weight regain // Diabetes 2001; 50: 2172-6.
24. Prunier C., Hocevar B. A., Howe P. H. Wnt signaling: physiology and pathology. // Growth Factors 2004; 22:141-150
25. Ranjith N., Pegoraro R. J., Naidoo D. P. et al. Genetic Variants Associated with Insulin Resistance and Metabolic Syndrome in Young Asian Indians with Myocardial Infarction. // Metabolic Syndrome and Related Disorders 2008; 6(3): 209-14.
26. Ritchie S. A., Ewart M.-N., Perry C. G. et al. The role of insulin and the adipocytokines in regulation of vascular endothelial function // Clinical Science 2004; 107: 519-32.
27. Rosen E. D., Spiegelman B. M. PPARgamma : a nuclear regulator of metabolism, dif-ferentiation, and cell growth. // J Biol Chem 2001; 276: 37731-4.
28. Schafer S. A., Tschritter O., Machicao F. Impaired glucagon-like peptide- 1-induced insu-lin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms // Diabetologia 2007; 50: 2443-50.
29. Shimabukuro M., Ohneda M., Lee Y., Unger R. H. Role of nitric oxide in obesity-induced beta cell disease // J Clin Invest 1997; 100(2): 290-5.
30. Tan G. D., Neville M. J., Liverani E. et al. The in vivo effects of the Pro12Ala PPAR 2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank // Diabetologia 2006; 49(1): 158-68.
31. Tushuizen M. E., Diamant M., Heine R. J. Postprandial dysmetabolism and cardiovascu-lar disease in type 2 diabetes // Postgrad Medical J 2005; 81: 1-6.
32. Walczak R., Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPAR in the control of lipid metabolism // J Lipid Res 2002; 43: 177-86.
33. Vaccaro O., Lapice E., Monticelli A. et al. Pro12Ala polymorphism of the PPARgamma 2 locus modulates the relationship between energy intake and body weight in type 2 dia-betic patients // Diabetes Care 2007; 30(5): 1156-61.
34. Yi F., Brubaker P. L., Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta // J Biol Chem 2005; 280:1457-64
35. Zimmet P., Shaw J., Alberti G. Preventing type 2 diabetes and the dysmetabolic syn-drome in the real world: a realistic view // Diabetic medicine 2003; 20(9): 693-702.
Review
For citations:
Mkrtumyan A.M., Biryukova E.V., Markina N.V. Molekulyarno-geneticheskie osobennosti, kharakter metabolizma glyukozy i funktsiya endoteliya u bol'nykh metabolicheskim sindromom russkoy populyatsii. Diabetes mellitus. 2008;11(4):26-30. https://doi.org/10.14341/2072-0351-5585
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
